Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2017

View Archived Issues

New phase I trial explores MK-2118 alone and with pembrolizumab for solid tumors and lymphomas

Amgen conducts phase I study of AMG-673 in relapsed or refractory AML

MJFF awards grant to Mitochon to help develop its mitochondrial-targeted compounds for Parkinson's

FDA accepts IND for gene-edited cell therapy for beta-thalassemia

Exelixis earns milestone from BMS for RORgammat inverse agonist program

MD Anderson and BridgeBio launch new company

Viking Therapeutics' VK-0214 shows promise in in vivo model

Siamab Therapeutics enters cancer immunology collaboration with Boehringer Ingelheim

Soluble Nogo-B a potential treatment for diabetic glomerulopathy

Vitruvian BioMedical obtains license to Alzheimer's disease vaccine candidate

Neon Therapeutics enters agreement with NKI to advance NEO-PTC-01 into clinic

PAX8 gene tied to gestational diabetes

Intercept Pharmaceuticals divulges novel farnesoid X receptor agonists

Cullinan Oncology announces USD 150 million series A financing

Novel vaccines for candidiasis created at Spanish centers

Amgen and CytomX collaborate in immuno-oncology

Catabasis reports open-label extension data for edasalonexent in Duchenne muscular dystrophy

Janssen Vaccines & Prevention present novel influenza B neuraminidase antibodies

Palleon Pharmaceuticals completes series A financing to advance glycoimmune checkpoint pipeline

Medy-Tox patents antibodies targeting CD3 gamma epsilon

Vantia reports phase III topline data on fedovapagon for nocturia in men with BPH

Children's Hospital of Philadelphia, Penn disclose nucleic acids encoding progranulin

Ligand Pharmaceuticals to acquire Crystal Bioscience

NIH grant supports exploration of NVP-015 for use against chemical threats

Identification of receptor for GDF15 allows development of treatments for weight-related conditions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...